Outcome measures at the end of 12 months according to disease type
| Variables | nAMD (N=50) | DMO (N=37) | RVO (N=30) | P value* |
| BCVA change (ETDRS letters) | 5 (−30 to 40) | 2 (−5 to 20) | 11 (−20 to 35) | 0.032† |
| CMT change (μm) | −41.5 (−340 to 81) | −54 (−482 to 50) | −137 (−478 to 43) | 0.022‡ |
| No of Injections | 10 (5 to 17) | 9 (3 to 13) | 10 (5 to 13) | 0.028§ |
| Final BCVA (ETDRS letters) | 66.5 (20 to 85) | 72 (0 to 85) | 68 (0 to 80) | 0.024¶ |
| Final CMT (μm) | 282.5 (195 to 551) | 296 (226 to 532) | 288 (222 to 710) | 0.242 |
Data are medians (range).
*P values are global p values testing for a difference between any of the diseases. (Kruskal-Wallis for continuous variables). For comparisons that are significant at the global level, adjusted pairwise p values for individual study comparisons are reported. Significant p values are bolded.
†nAMD vs DMO p=0.494; DMO vs RVO p=0.027; nAMD vs RVO p=0.417.
‡nAMD vs DMO p=1.000; DMO vs RVO p=0.033; nAMD vs RVO p=0.046.
§nAMD vs DMO p=0.019; DMO vs RVO p=0.498; nAMD vs RVO p=1.000.
¶nAMD vs DMO p=0.019; DMO vs RVO p=0.498; nAMD vs RVO p=0.834.
BCVA, best-corrected visual acuity; CMT, central macular thickness; DMO, diabetic macular oedema; ETDRS, early treatment diabetic retinopathy study; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion.